INT37139

Context Info Confidence 0.38 First Reported 1986 Last Reported 2010 Negated 3 Speculated 0 Reported most in Abstract Documents 9 Total Number 9 Disease Relevance 4.33 Pain Relevance 4.46

mitochondrion (Fdps) nucleolus (Fdps) peroxisome (Fdps) nucleus (Fdps) cytoplasm (Fdps)

Anatomy Link Frequency osteoclasts 1 Fdps (Rattus norvegicus)

Pain Link Frequency Relevance Heat pain suppression 4 99.68 Pain 29 97.24 Central nervous system 3 97.24 cINOD 8 94.56 central sensitization 1 94.32 Lasting pain 7 92.24 Antinociceptive 2 90.88 Glutamate 40 88.56 COX-2 inhibitor 1 84.40 Hyperalgesia 5 84.00

Disease Link Frequency Relevance Heat Pain 43 99.68 Stress 4 99.34 Cancer 37 98.44 Nociception 3 95.80 Breast Cancer 1 93.72 INFLAMMATION 12 92.16 Hypercalcemia 15 90.04 Fever 1 86.56 Pressure And Volume Under Development 3 85.60 Hyperalgesia 6 84.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

RESULTS: Morphine and buprenorphine had parallel dose-response curves in blocking FPS, with buprenorphine 40 times more potent than morphine.

Negative_regulation (blocking) of FPS

1) Confidence 0.38 Published 2008 Journal Psychopharmacology (Berl.) Section Body Doc Link 18324390 Disease Relevance 0 Pain Relevance 0

A concern, however, with increased involvement is that FPs receive little oncological training in medical school [4], and thus, are not adequately prepared for involvement in certain aspects of cancer care particularly as treatment practices change as new evidence emerges.

Neg (not) Negative_regulation (prepared) of FPs associated with cancer

2) Confidence 0.36 Published 2004 Journal BMC Fam Pract Section Body Doc Link PMC535864 Disease Relevance 0.32 Pain Relevance 0.07

The gastro-erosive activity of phenylbutazone and FPP028 was studied in restraint-stressed rats; in such test the ulcerogenic activity of phenylbutazone appeared to be dose-related; conversely, FPP028 demonstrated a gastro-protective effect since the number of gastric lesions induced either by stress or phenylbutazone treatment was decreased bu FPP028.

Negative_regulation (decreased) of FPP028 associated with stress

3) Confidence 0.31 Published 1986 Journal Pharmacol Res Commun Section Abstract Doc Link 3487802 Disease Relevance 0.61 Pain Relevance 0.34

At the higher frequencies (50-100 Hz) however, there was no reduction in the FPs and no pain suppression.

Neg (no) Negative_regulation (reduction) of FPs associated with pain suppression

4) Confidence 0.18 Published 2002 Journal Pain Section Abstract Doc Link 12031778 Disease Relevance 0.91 Pain Relevance 1.17

At the higher frequencies (50-100 Hz), however, there was no reduction in the FPs and no pain suppression.

Neg (no) Negative_regulation (reduction) of FPs associated with pain suppression

5) Confidence 0.18 Published 2003 Journal Pain Section Abstract Doc Link 12507704 Disease Relevance 0.98 Pain Relevance 1.29

Along with HMG CoA reductase, bisphosphonate is also known to decrease FPP levels primarily by inhibiting farnesyl diphosphate synthase (FPPS) [34].

Negative_regulation (decrease) of FPP

6) Confidence 0.14 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2996792 Disease Relevance 0.66 Pain Relevance 0.63

In striatal slices, acute QA application dramatically inhibited corticostriatal field potentials (FPs), whose recovery was significantly higher in CNTF rats compared to controls (?

Negative_regulation (inhibited) of FPs

7) Confidence 0.13 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2798716 Disease Relevance 0 Pain Relevance 0.22

The objective of the present study was to examine the efficacy and the gastric side effects of 1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3), a synthetic dual inhibitor of COX/5-LOX.

Negative_regulation (inhibitor) of FPP-3

8) Confidence 0.10 Published 2006 Journal Biol. Pharm. Bull. Section Abstract Doc Link 16462046 Disease Relevance 0.68 Pain Relevance 0.67

Bisphosphonates in the potent, N-containing group (including pamidronate, alendronate, risedronate, ibandronate, and zoledronate) inhibit the mevalonate pathway in osteoclasts, in particular the farnesyl pyrophosphate synthase.

Negative_regulation (inhibit) of farnesyl pyrophosphate synthase in osteoclasts

9) Confidence 0.05 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661644 Disease Relevance 0.17 Pain Relevance 0.06

General Comments

This test has worked.